Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2021-05-24
Target enrollment:
Participant gender:
Summary
Nivolumab (brand name Opdivo): IV, administered per standard of care according to
institutional guidelines at the discretion of the treating medical oncologist, until disease
progression or unacceptable toxicity; SABR, dose variable, in 1-3 fractions.